Potential Biomarker Identified for Alzheimer's Disease
By LabMedica International staff writers Posted on 18 Aug 2014 |
A genome-wide association study (GWAS) has been conducted on family-based cohorts using an approach that accounts for family structure and calculates a risk score for Alzheimer's Disease (AD) as the outcome.
Links between the most promising gene candidate and AD pathogenesis were explored in silico as well as experimentally in cell-based models and in human brain to identify novel AD loci using a unique family-based approach that can detect robust associations with infrequent variants such as minor allele frequency.
Scientists at the Boston University School of Medicine (Boston, MA, USA) obtained data from the Framingham Heart Study cohort and then confirmed their finding in a larger dataset from the Alzheimer's Disease Genetics Consortium and other datasets. The team used many different techniques to obtain the required information including enzyme-linked immunosorbent assays (ELISA), sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blotting, primary neuron culture and tau immunofluorescence, and analyses of gene expression in the brain.
The ELISAs were carried out using the human Aβ40 and Aβ42 kits (Invitrogen; Carlsbad, CA, USA) and quantitative polymerase chain reactions (PCRs) were run on an ABI 7900HT real-time machine (Applied Biosystems; Foster City, CA, USA). The scientists found that variants in a new gene, Plexin A4 (PLXNA4), may increase the risk of developing Alzheimer's disease (AD). A form of the protein encoded by this gene promotes formation of neurofibrillary tangles consisting of decomposed tau protein, one of the two pathological hallmarks of the disease. There was strong evidence of an association with several single nucleotide polymorphisms in PLXNA4, a gene which had not been previously linked to AD.
Lindsay Farrer, PhD, the senior author of the study said, “We showed that PLXNA4 affects the processing of tau as it relates to neurofibrillary tangles, the primary marker of AD. Most drugs that have been developed or that are in development for treating AD are intended to reduce the toxic form of beta-amyloid, a sticky substance that accumulates in the brain of persons with AD, and none have been very effective. Only a few drugs have targeted the tau pathway.” The study was published on July 29, 2014, in the journal Annals of Neurology.
Related Links:
Boston University School of Medicine
Invitrogen
Applied Biosystems
Links between the most promising gene candidate and AD pathogenesis were explored in silico as well as experimentally in cell-based models and in human brain to identify novel AD loci using a unique family-based approach that can detect robust associations with infrequent variants such as minor allele frequency.
Scientists at the Boston University School of Medicine (Boston, MA, USA) obtained data from the Framingham Heart Study cohort and then confirmed their finding in a larger dataset from the Alzheimer's Disease Genetics Consortium and other datasets. The team used many different techniques to obtain the required information including enzyme-linked immunosorbent assays (ELISA), sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blotting, primary neuron culture and tau immunofluorescence, and analyses of gene expression in the brain.
The ELISAs were carried out using the human Aβ40 and Aβ42 kits (Invitrogen; Carlsbad, CA, USA) and quantitative polymerase chain reactions (PCRs) were run on an ABI 7900HT real-time machine (Applied Biosystems; Foster City, CA, USA). The scientists found that variants in a new gene, Plexin A4 (PLXNA4), may increase the risk of developing Alzheimer's disease (AD). A form of the protein encoded by this gene promotes formation of neurofibrillary tangles consisting of decomposed tau protein, one of the two pathological hallmarks of the disease. There was strong evidence of an association with several single nucleotide polymorphisms in PLXNA4, a gene which had not been previously linked to AD.
Lindsay Farrer, PhD, the senior author of the study said, “We showed that PLXNA4 affects the processing of tau as it relates to neurofibrillary tangles, the primary marker of AD. Most drugs that have been developed or that are in development for treating AD are intended to reduce the toxic form of beta-amyloid, a sticky substance that accumulates in the brain of persons with AD, and none have been very effective. Only a few drugs have targeted the tau pathway.” The study was published on July 29, 2014, in the journal Annals of Neurology.
Related Links:
Boston University School of Medicine
Invitrogen
Applied Biosystems
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans